CooperVision MiSight 1 day Contact Lenses (IMAGE) McDougall Communications Caption CooperVision, a world leader in myopia control and management for children, has announced new seven-year findings from its pivotal MiSight® 1 day contact lens clinical trial. Twelve months following treatment cessation, mean axial elongation data indicate no evidence of rebound effect, meaning the myopia control gains are retained. Credit CooperVision Usage Restrictions None License Original content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.